Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060620 | 0.93 | SCN9A (0.54) | SCN9ASCN3ASCN1ASCN2ASCN10A | |
| SCHEMBL3060265 | 0.92 | SCN3A (0.51) | SCN9ASCN3ASCN1ASCN2ASCN10A | |
| SCHEMBL3064189 | 0.91 | SCN3A (0.46) | SCN9ASCN3ASCN1ASCN2ASCN10A | |
| SCHEMBL3066154 | 0.89 | SCN9A (0.47) | SCN9ASCN3ASCN1ASCN2ASCN10A | |
| SCHEMBL3058512 | 0.86 | SCN3A (0.57) | SCN9ASCN3ASCN1A | |
| SCHEMBL3064550 | 0.85 | SCN3A (0.47) | SCN9ASCN3ASCN1ASCN2ASCN10A | |
| SCHEMBL3063891 | 0.84 | SCN3A (0.65) | SCN9ASCN3ASCN1ASCN2ASCN10A | |
| SCHEMBL3055423 | 0.84 | SCN3A (0.49) | SCN9ASCN3ASCN1ASCN2ASCN10A | |
| SCHEMBL3073762 | 0.83 | SCN3A (0.44) | SCN9ASCN3A | |
| SCHEMBL3055718 | 0.80 | SCN3A (0.51) | SCN9ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20100267782-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2175728-A1 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009012241-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357685-A1 | Sodium Channel Inhibitors | TRPV1, SCN1A, SCN2A | SCN9A 19/4885SCN3A 8/4885SCN1A 2/4885 |
| US-20100267782-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | SCN9A 19/4885SCN3A 8/4885SCN1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.